Risk of new disease activity in patients with multiple sclerosis who continue or discontinue disease-modifying therapies (DISCOMS): a multicentre, randomised, single-blind, phase 4, non-inferiority trial

Authors: John R. Corboy, Robert J. Fox, Ilya Kister, Gary Cutter, Charity J. Morgan, Rebecca Seale, Eric Engebretson, Tarah Gustafson, Aaron E. Miller, Dennis Bourdette, Vijayshree Yadav, Andrew Goodman, Michael K. Racke, Robert J. Fallis, Carlo Tornatore, Myla Goldman, Meena Kannan, Subramaniam Sriram, Joseph R. Berger, Anne H. Cross, Kottil Rammohan, Zongqi Xia, Thomas Leist, Sharon Lynch, Eric C. Klawiter, Lilyana Amezcua, James D. Bowen - The Lancet 2023 cited by 136